American Association of Individual Investors2h
Which Is a Better Investment, Corcept Therapeutics Incorporated or Novartis AG Stock?
Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN)
In a report released today, Emily Field from Barclays maintained a Sell rating on Novartis AG (NOVN – Research Report), with a price target of ...
pharmaphorum20h
Novartis eyes New Year verdict from FDA on delayed Leqvio
Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date of 1 ...